VanEck Biotech ETF
BBH
78 hedge funds and large institutions have $85.6M invested in VanEck Biotech ETF in 2016 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 20 increasing their positions, 33 reducing their positions, and 6 closing their positions.
120% more call options, than puts
Call options by funds: $9.51M | Put options by funds: $4.32M
117% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 6
10% more funds holding
Funds holding: 71 → 78 (+7)
6.7% less ownership
Funds ownership: 22.25% → 15.56% (-6.7%)
28% less capital invested
Capital invested by funds: $120M → $85.6M (-$33.9M)
39% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TH
Timber Hill
Greenwich,
Connecticut
|
+$1.92M |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$1.74M |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
+$1.14M |
| 4 |
Millennium Management
New York
|
+$757K |
| 5 |
VF
Virtu Financial
New York
|
+$638K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$13M |
| 2 |
Citigroup
New York
|
-$5.31M |
| 3 |
LFM
Lumina Fund Management
New York
|
-$3.7M |
| 4 |
LPL Financial
San Diego,
California
|
-$3.61M |
| 5 |
Goldman Sachs
New York
|
-$3.14M |
BBH Hedge Fund Activity: Q2 2016 in Review
78 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q2 2016, worth a combined $85.6M — down 28% from $120M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new BBH positions and 6 closed out — a net gain of 7 holders — while 20 added to existing stakes and 33 trimmed.
The largest buyer was Timber Hill, adding an estimated $1.92M. The largest seller was Morgan Stanley, cutting an estimated $13M.
- 78 institutional investors held VanEck Biotech ETF (BBH) as of Q2 2016, up from 71 in Q1 2016.
- Funds reported $85.6M of VanEck Biotech ETF stock for Q2 2016, down 28% quarter-over-quarter.
- 13 funds opened new VanEck Biotech ETF positions in Q2 2016 and 6 closed out, a net change of +7 holders.
- The largest VanEck Biotech ETF buyer in Q2 2016 was Timber Hill, an estimated $1.92M added.
- The largest VanEck Biotech ETF seller in Q2 2016 was Morgan Stanley, an estimated $13M sold.
Based on aggregated 13F filings for Q2 2016.